BOSTON--(BUSINESS WIRE)--Penumbra, Inc. (NYSE:PEN), a global interventional therapies company, today announced U.S. commercial availability of its most advanced thrombectomy device, the ACE™68 ...
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum ...
Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot ...
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly ...
Lightning Flash™ 2.0 features advanced computer assisted vacuum thrombectomy (CAVT) software, designed for increased efficiency and sensitivity to enhance removal of venous thrombus and treatment of ...
Please provide your email address to receive an email when new articles are posted on . An FDA-cleared computer-assisted vacuum thrombectomy system was launched. The next-generation system is designed ...
Penumbra PEN is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are ...
Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Penumbra (PEN – Research Report), with a price target of $264.00. Ryan Zimmerman has given his Buy rating due to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results